UFP Technologies (UFPT) recently celebrated a period of exceptional financial achievement, announcing record-setting performance for the second quarter of 2026. The company experienced a notable 15.1% surge in net sales, alongside an impressive 16.8% increase in adjusted earnings per share, reaching an all-time high of $2.92. This success is largely credited to a comprehensive expansion across its MedTech business segments and strategic investments aimed at bolstering leadership capacity and infrastructure, notably within its Dominican Republic operations. Despite minor delays in realizing the full benefits of certain program transfers, the company's forward-looking strategy includes aggressive pursuit of acquisitions to solidify its standing in the medical technology sector.
The earnings call, held on Monday, August 3, 2026, at 9:00 a.m. ET, featured key presentations from President and CEO Mitchell Rock and Chief Financial Officer Ronald Lataille. Their discussions illuminated the company's strategic direction and recent accomplishments. Mitchell Rock's inaugural earnings call as CEO underscored a seamless transition, emphasizing continuity in the successful strategies that have propelled UFP Technologies' growth. He highlighted the company's unwavering commitment to customer support, team development, calculated investments, and the consistent pursuit of value-enhancing acquisitions for shareholders.
During the quarter, UFP Technologies' sales soared to $174 million, a testament to the robust performance across its diverse platform. The gross margin saw an uptick to 29.3% from the previous year's 28.8%, even as the company navigated margin pressures from the ongoing transfer of programs to the Dominican Republic. Organic sales growth stood strong at 12.4%, driven by accelerated program rollouts and enhanced production capabilities at the AJR facility. The MedTech division, excluding its top five clients, recorded an impressive 19.7% growth, illustrating the broad applicability of its product range and the resilience of its offerings. Growth from the top five customers also remained robust, increasing by 14.7% due to heightened volume and demand across a vast array of validated product codes. Conversely, non-medical sales remained stable as the company strategically prioritized MedTech initiatives and capacity. Selling, General, and Administrative (SG&A) expenses amounted to $22.8 million, an increase of $4.1 million, primarily allocated to strengthening leadership and back-office infrastructure. Adjusted SG&A represented 11.7% of sales, up from 10.8% in the corresponding period last year. Additional labor and benefits costs of $1.9 million were invested in business development, operations, and legal personnel to support future expansion. Non-cash equity compensation also rose by $1 million, partly due to the CEO transition costs.
The company generated $15.6 million in cash from operations, earmarked for ongoing investments and strategic ventures. Capital expenditures for the quarter were $1.2 million, focused on upgrading facilities and manufacturing equipment. UFP Technologies boasts a leverage ratio of less than 1x, providing substantial financial flexibility for future capital deployment and acquisitions. Adjusted EBITDA reached $36.4 million, marking a 14.3% increase over the second quarter of 2025. The company's acquisition pipeline is active, with 5 to 10 opportunities under consideration, primarily targeting businesses in lucrative MedTech markets, with target EBITDA values ranging from $5 million to $30 million per opportunity. Robotic-assisted surgery programs, launched in November, are projected to contribute an eight-figure sum by 2027 as production scales up. Three new programs are in various stages of transition from external sources, with two already relocated to the Dominican Republic. The backlog at AJR has been fully cleared, and the St. Charles facility is now operating at full capacity. Submarket performance in cardiovascular, infection control, and orthopedics remained strong, though the robotic surgical market is expected to remain flat or decline for the year. Management also acknowledged persistent inflationary pressures on raw material costs, particularly petroleum-based inputs, exacerbated by global conflicts impacting oil prices.
The leadership team of UFP Technologies, Inc. (UFPT) has articulated a future outlook rooted in robust expansion and operational excellence. They anticipate organic growth targets for the remainder of the year to align with the long-term range of 6% to 9%, as year-over-year comparisons normalize. This projection follows the successful resolution of past labor inefficiencies and the continued strategic development of their global platform. The company's diversified customer base and extensive product portfolio are expected to sustain this growth trajectory, underpinned by a disciplined approach to capital allocation and ongoing investments in human capital and operational capabilities.
